KR20020093017A - 포유동물 스핑고신 키나제 유형 2 이성체, 이의 클로닝,발현 및 사용 방법 - Google Patents

포유동물 스핑고신 키나제 유형 2 이성체, 이의 클로닝,발현 및 사용 방법 Download PDF

Info

Publication number
KR20020093017A
KR20020093017A KR1020027013149A KR20027013149A KR20020093017A KR 20020093017 A KR20020093017 A KR 20020093017A KR 1020027013149 A KR1020027013149 A KR 1020027013149A KR 20027013149 A KR20027013149 A KR 20027013149A KR 20020093017 A KR20020093017 A KR 20020093017A
Authority
KR
South Korea
Prior art keywords
sphingosine kinase
kinase type
cell
vector
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020027013149A
Other languages
English (en)
Korean (ko)
Inventor
스피겔사라
고하마다까후미
Original Assignee
상꾜 가부시키가이샤
조지타운 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상꾜 가부시키가이샤, 조지타운 유니버시티 filed Critical 상꾜 가부시키가이샤
Publication of KR20020093017A publication Critical patent/KR20020093017A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020027013149A 2000-04-03 2001-03-26 포유동물 스핑고신 키나제 유형 2 이성체, 이의 클로닝,발현 및 사용 방법 Withdrawn KR20020093017A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19431800P 2000-04-03 2000-04-03
US60/194,318 2000-04-03
US09/817,676 US6800470B2 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
PCT/US2001/009664 WO2001074837A1 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
US09/817,676 2001-03-26

Publications (1)

Publication Number Publication Date
KR20020093017A true KR20020093017A (ko) 2002-12-12

Family

ID=26889896

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027013149A Withdrawn KR20020093017A (ko) 2000-04-03 2001-03-26 포유동물 스핑고신 키나제 유형 2 이성체, 이의 클로닝,발현 및 사용 방법

Country Status (9)

Country Link
US (4) US6800470B2 (enExample)
JP (1) JP4584525B2 (enExample)
KR (1) KR20020093017A (enExample)
AU (1) AU5100201A (enExample)
CA (1) CA2404965A1 (enExample)
DK (1) DK1268509T3 (enExample)
HU (1) HUP0301691A3 (enExample)
MX (1) MXPA02009781A (enExample)
WO (1) WO2001074837A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1268509T3 (da) * 2000-04-03 2010-03-08 Daiichi Sankyo Co Ltd Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
JP2005522999A (ja) * 2002-01-31 2005-08-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 癌を処置するための方法および組成物
WO2004035786A1 (en) * 2002-10-14 2004-04-29 Medvet Science Pty. Ltd. A method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase
AU2003292636A1 (en) * 2002-12-27 2004-07-29 The New Industry Research Organization Cell growth inhibitor using sphingosine kinase 2, method of constructing fused protein having its nuclear localization signal, method of screening drug candidate, and screening kit
US8372888B2 (en) * 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
US8314151B2 (en) 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10675255B2 (en) 2017-06-23 2020-06-09 Enzo Bochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374616A (en) * 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
AU4097999A (en) * 1998-05-26 1999-12-13 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
AU3828301A (en) * 2000-02-14 2001-08-27 Curagen Corp Novel sphingosine kinases
DK1268509T3 (da) * 2000-04-03 2010-03-08 Daiichi Sankyo Co Ltd Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf

Also Published As

Publication number Publication date
US7419814B2 (en) 2008-09-02
US6800470B2 (en) 2004-10-05
US7803595B2 (en) 2010-09-28
CA2404965A1 (en) 2001-10-11
JP2004500117A (ja) 2004-01-08
JP4584525B2 (ja) 2010-11-24
US20120107833A1 (en) 2012-05-03
US20020042101A1 (en) 2002-04-11
MXPA02009781A (es) 2004-09-06
DK1268509T3 (da) 2010-03-08
US20040203104A1 (en) 2004-10-14
US8263349B2 (en) 2012-09-11
US20090169555A1 (en) 2009-07-02
WO2001074837A1 (en) 2001-10-11
AU5100201A (en) 2001-10-15
HUP0301691A2 (hu) 2003-08-28
HUP0301691A3 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
US8263349B2 (en) Antibody specific for a mammalian sphingosine kinase type 2 isoform protein and methods of use thereof
WO1999061581A2 (en) Sphingosine kinase, cloning, expression and methods of use
US5914261A (en) Family of MAP2 protein kinases
EP1268509B1 (en) Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
US6511825B1 (en) Cell signaling polypeptides and nucleic acids
US6830916B2 (en) Sphingosine kinase, cloning, expression and methods of use
US6797501B2 (en) Protein tyrosine phosphatase PTP20 and related products and methods
JP2002539780A (ja) 酵 素
KR20080023729A (ko) 미토겐-활성화 단백질 키나아제의 신규 인산화 자리, 변형단백질 및 적용
AU2001251002A1 (en) Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
US20040185460A1 (en) Novel mixed lineage kinase (7) (mlk7) polypeptide polynucleotides encoding the same and methods of use thereof
JP4516747B2 (ja) インスリン作用促進能力の検定方法
US20030176375A1 (en) Method of treating anemia
JP2006111557A (ja) Ｔｘｋ複合体およびその利用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20021001

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid